Mounjaro Payment Plans: What the Evidence Says About Cost and Access

What NICE and clinical evidence tell us about Mounjaro's value

NICE recommended tirzepatide in Technology Appraisal TA1026, published December 2024, on the basis of evidence from the SURMOUNT clinical programme. In the largest trial, involving more than 2,500 adults with obesity and no diabetes, participants at the highest dose saw average body-weight reductions of around 20–21% over 72 weeks. That scale of outcome, set against the well-documented health costs of obesity, is precisely why the question of affordability matters, and why it attracts so much searching.

For context on private pricing: Eli Lilly revised Mounjaro's UK list price upwards from September 2025, and typical private-market prices now run roughly £149–£375 per month depending on the dose and the provider. Those figures are widely reported and give a reasonable frame of reference. What they do not tell you is what is included. A headline price from one clinic might cover the medicine only; another might bundle in clinical consultations, ongoing prescriber reviews and aftercare support. Comparing headline numbers without knowing what each one contains is a little like comparing quoted rents without checking whether bills are included.

If you want a clearer picture of how Mounjaro pricing stacks up between providers, our cost breakdown page sets out what these figures typically do and do not include, without any per-pen marketing claims.

How Mounjaro 'payment plans' actually work in practice

A genuine Mounjaro payment plan does not exist in any regulated clinical sense. What providers sometimes offer is a credit arrangement through a third-party finance company, most commonly a buy-now-pay-later service. These let a patient pay the provider in installments rather than as a lump sum each month. The prescription process itself is entirely unchanged: a GPhC-registered prescriber still reviews the consultation, a pharmacy still dispenses, and the medicine still arrives through the licensed UK supply chain.

There is a common misconception that spreading the cost means receiving more medicine upfront, that you might pay weekly and receive a larger initial supply. That is not how it works. Dispensing is tied to the prescribing cycle, and repeat prescriptions require a fresh clinical review before each supply. The payment structure and the clinical structure are separate.

If you are specifically wondering about arrangements marketed as Klarna-style payment options for Mounjaro, or weekly payment schedules, those pages explain the mechanics in detail. The short version: they are credit products, and the same rules about clinical assessment apply regardless of how you pay.

What nume, sorry, what legitimate private services include in their pricing

At nume, we do not offer financing arrangements, installment plans or third-party credit. Our pricing is structured differently: one transparent amount covers the consultation, the prescription, the medicine and free next-working-day delivery via DPD. There are no subscriptions, and every repeat requires a fresh prescriber review, a real clinician reads your notes, not a system that approves automatically.

We are not the cheapest option on the market. We made that choice deliberately. A clinical review before every supply, seven-day aftercare and identity and weight verification on video are not features that sit comfortably alongside a race to the lowest price. For a prescription medicine, the question that matters is not which provider charges least but which one gives you a safe, genuine supply with proper clinical oversight throughout.

Anyone considering treatment can read about how tirzepatide works, review our treatment plan overview, or explore the broader weight-loss treatment options we offer before making any decision. Our clinical team is there throughout.

NHS tirzepatide access, what the phased rollout means for cost

For some people, the most practical 'payment plan' is the NHS itself. Tirzepatide became available on the NHS from June 2025 for adults with a BMI of 40 or above and four or more qualifying weight-related conditions (including type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease). A second cohort (BMI 35–39.9 with four or more conditions) became eligible from June 2026. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

NHS access is free at the point of use, but the eligibility criteria are strict and phased, and waiting lists through specialist weight management services can be long. Private prescription is a regulated alternative for people who fall outside current NHS thresholds or who do not want to wait. Both routes require a prescriber to assess suitability, the NHS does not bypass that step, and neither does a legitimate private clinic.

If you are unsure which route applies to you, the NHS England guidance on weight management injections sets out the NHS criteria clearly. Our frequently asked questions cover the private route in plain terms. When you are ready to talk through your own situation, you can check your eligibility with our prescribers at no cost.